Cargando…
Neoantigens as potential vaccines in hepatocellular carcinoma
BACKGROUND: Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not been invest...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066373/ https://www.ncbi.nlm.nih.gov/pubmed/35193931 http://dx.doi.org/10.1136/jitc-2021-003978 |
_version_ | 1784699790142996480 |
---|---|
author | Repáraz, David Ruiz, Marta Llopiz, Diana Silva, Leyre Vercher, Enric Aparicio, Belén Egea, Josune Tamayo-Uria, Ibon Hervás-Stubbs, Sandra García-Balduz, Jorge Castro, Carla Iñarrairaegui, Mercedes Tagliamonte, Maria Mauriello, Angela Cavalluzzo, Beatrice Buonaguro, Luigi Rohrer, Charlotte Heim, Kathrin Tauber, Catrin Hofmann, Maike Thimme, Robert Sangro, Bruno Sarobe, Pablo |
author_facet | Repáraz, David Ruiz, Marta Llopiz, Diana Silva, Leyre Vercher, Enric Aparicio, Belén Egea, Josune Tamayo-Uria, Ibon Hervás-Stubbs, Sandra García-Balduz, Jorge Castro, Carla Iñarrairaegui, Mercedes Tagliamonte, Maria Mauriello, Angela Cavalluzzo, Beatrice Buonaguro, Luigi Rohrer, Charlotte Heim, Kathrin Tauber, Catrin Hofmann, Maike Thimme, Robert Sangro, Bruno Sarobe, Pablo |
author_sort | Repáraz, David |
collection | PubMed |
description | BACKGROUND: Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not been investigated. Our aim was to analyze whether tumors in HCC patients contain immunogenic neoantigens suitable for future use in therapeutic vaccination. METHODS: Whole-exome sequencing and RNAseq were performed in a cohort of fourteen HCC patients submitted to surgery or liver transplant. To identify mutations, single-nucleotide variants (SNV) originating non-synonymous changes that were confirmed at the RNA level were analyzed. Immunogenicity of putative neoAgs predicted by HLA binding algorithms was confirmed by using in vitro HLA binding assays and T-cell stimulation experiments, the latter in vivo, by immunizing HLA-A*02.01/HLA-DRB1*01 (HHD-DR1) transgenic mice, and in in vitro, using human lymphocytes. RESULTS: Sequencing led to the identification of a median of 1217 missense somatic SNV per patient, narrowed to 30 when filtering by using RNAseq data. A median of 13 and 5 peptides per patient were predicted as potential binders to HLA class I and class II molecules, respectively. Considering only HLA-A*02.01- and HLA-DRB1*01-predicted binders, 70% demonstrated HLA-binding capacity and about 50% were immunogenic when tested in HHD-DR1 mice. These peptides induced polyfunctional T cells that specifically recognized the mutated but not the wild-type sequence as well as neoantigen-expressing cells. Moreover, coimmunization experiments combining CD8 and CD4 neoantigen epitopes resulted in stronger CD8 T cell responses. Finally, responses against neoantigens were also induced in vitro using human cells. CONCLUSION: These results show that mutations in HCC tumors may generate immunogenic neoantigens with potential applicability for future combinatorial therapeutic strategies. |
format | Online Article Text |
id | pubmed-9066373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-90663732022-05-12 Neoantigens as potential vaccines in hepatocellular carcinoma Repáraz, David Ruiz, Marta Llopiz, Diana Silva, Leyre Vercher, Enric Aparicio, Belén Egea, Josune Tamayo-Uria, Ibon Hervás-Stubbs, Sandra García-Balduz, Jorge Castro, Carla Iñarrairaegui, Mercedes Tagliamonte, Maria Mauriello, Angela Cavalluzzo, Beatrice Buonaguro, Luigi Rohrer, Charlotte Heim, Kathrin Tauber, Catrin Hofmann, Maike Thimme, Robert Sangro, Bruno Sarobe, Pablo J Immunother Cancer Basic Tumor Immunology BACKGROUND: Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not been investigated. Our aim was to analyze whether tumors in HCC patients contain immunogenic neoantigens suitable for future use in therapeutic vaccination. METHODS: Whole-exome sequencing and RNAseq were performed in a cohort of fourteen HCC patients submitted to surgery or liver transplant. To identify mutations, single-nucleotide variants (SNV) originating non-synonymous changes that were confirmed at the RNA level were analyzed. Immunogenicity of putative neoAgs predicted by HLA binding algorithms was confirmed by using in vitro HLA binding assays and T-cell stimulation experiments, the latter in vivo, by immunizing HLA-A*02.01/HLA-DRB1*01 (HHD-DR1) transgenic mice, and in in vitro, using human lymphocytes. RESULTS: Sequencing led to the identification of a median of 1217 missense somatic SNV per patient, narrowed to 30 when filtering by using RNAseq data. A median of 13 and 5 peptides per patient were predicted as potential binders to HLA class I and class II molecules, respectively. Considering only HLA-A*02.01- and HLA-DRB1*01-predicted binders, 70% demonstrated HLA-binding capacity and about 50% were immunogenic when tested in HHD-DR1 mice. These peptides induced polyfunctional T cells that specifically recognized the mutated but not the wild-type sequence as well as neoantigen-expressing cells. Moreover, coimmunization experiments combining CD8 and CD4 neoantigen epitopes resulted in stronger CD8 T cell responses. Finally, responses against neoantigens were also induced in vitro using human cells. CONCLUSION: These results show that mutations in HCC tumors may generate immunogenic neoantigens with potential applicability for future combinatorial therapeutic strategies. BMJ Publishing Group 2022-02-22 /pmc/articles/PMC9066373/ /pubmed/35193931 http://dx.doi.org/10.1136/jitc-2021-003978 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Basic Tumor Immunology Repáraz, David Ruiz, Marta Llopiz, Diana Silva, Leyre Vercher, Enric Aparicio, Belén Egea, Josune Tamayo-Uria, Ibon Hervás-Stubbs, Sandra García-Balduz, Jorge Castro, Carla Iñarrairaegui, Mercedes Tagliamonte, Maria Mauriello, Angela Cavalluzzo, Beatrice Buonaguro, Luigi Rohrer, Charlotte Heim, Kathrin Tauber, Catrin Hofmann, Maike Thimme, Robert Sangro, Bruno Sarobe, Pablo Neoantigens as potential vaccines in hepatocellular carcinoma |
title | Neoantigens as potential vaccines in hepatocellular carcinoma |
title_full | Neoantigens as potential vaccines in hepatocellular carcinoma |
title_fullStr | Neoantigens as potential vaccines in hepatocellular carcinoma |
title_full_unstemmed | Neoantigens as potential vaccines in hepatocellular carcinoma |
title_short | Neoantigens as potential vaccines in hepatocellular carcinoma |
title_sort | neoantigens as potential vaccines in hepatocellular carcinoma |
topic | Basic Tumor Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066373/ https://www.ncbi.nlm.nih.gov/pubmed/35193931 http://dx.doi.org/10.1136/jitc-2021-003978 |
work_keys_str_mv | AT reparazdavid neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT ruizmarta neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT llopizdiana neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT silvaleyre neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT vercherenric neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT apariciobelen neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT egeajosune neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT tamayouriaibon neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT hervasstubbssandra neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT garciabalduzjorge neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT castrocarla neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT inarrairaeguimercedes neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT tagliamontemaria neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT maurielloangela neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT cavalluzzobeatrice neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT buonaguroluigi neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT rohrercharlotte neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT heimkathrin neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT taubercatrin neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT hofmannmaike neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT thimmerobert neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT sangrobruno neoantigensaspotentialvaccinesinhepatocellularcarcinoma AT sarobepablo neoantigensaspotentialvaccinesinhepatocellularcarcinoma |